Published in Gynecol Oncol on November 06, 2010
Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett (2012) 1.38
Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis. Int J Mol Sci (2012) 1.29
Anti-mullerian hormone is expressed by endometriosis tissues and induces cell cycle arrest and apoptosis in endometriosis cells. J Exp Clin Cancer Res (2014) 0.87
Regulation of the ovarian reserve by members of the transforming growth factor beta family. Mol Reprod Dev (2012) 0.84
Reduced migration of Ishikawa cells associated with downregulation of aquaporin-5. Oncol Lett (2012) 0.80
Reduced serum levels of anti-Müllerian hormone in females with inherited bone marrow failure syndromes. J Clin Endocrinol Metab (2014) 0.78
Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med (2016) 0.75
Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer. Cell Rep (2016) 0.75
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A (2006) 4.66
Id: a target of BMP signaling. Sci STKE (2002) 2.03
A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res (2002) 1.97
AMH and AMH receptor defects in persistent Müllerian duct syndrome. Hum Reprod Update (2005) 1.91
Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev (2001) 1.82
The type I serine/threonine kinase receptor ActRIA (ALK2) is required for gastrulation of the mouse embryo. Development (1999) 1.59
A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the müllerian duct. Development (1994) 1.54
Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor-beta type II receptor family. Dev Dyn (1993) 1.50
Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone. Mol Endocrinol (1994) 1.46
Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression. Mol Endocrinol (2001) 1.31
The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling. Mol Endocrinol (2001) 1.28
Insensitivity to anti-müllerian hormone due to a mutation in the human anti-müllerian hormone receptor. Nat Genet (1995) 1.27
Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression. Development (2006) 1.26
Developmental expression of a candidate müllerian inhibiting substance type II receptor. Endocrinology (1996) 1.26
Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor. J Biol Chem (2000) 1.25
Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway. J Biol Chem (2000) 1.22
Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci U S A (2010) 1.20
Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res (1999) 1.20
Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res (2002) 1.15
Mullerian inhibiting substance acts as a motor neuron survival factor in vitro. Proc Natl Acad Sci U S A (2005) 1.14
A graded organ culture assay for the detection of Mullerian inhibiting substance. J Surg Res (1977) 1.13
Chick pulmonary Wnt5a directs airway and vascular tubulogenesis. Development (2008) 1.10
Persistent Mullerian duct syndrome caused by both a 27-bp deletion and a novel splice mutation in the MIS type II receptor gene. Birth Defects Res A Clin Mol Teratol (2003) 1.07
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A (2006) 1.02
Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level. Endocrinology (1999) 1.02
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance. Proc Natl Acad Sci U S A (2004) 0.99
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo. Proc Natl Acad Sci U S A (2002) 0.99
Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecol Oncol (2007) 0.98
Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model. Proc Natl Acad Sci U S A (2005) 0.98
Mullerian Inhibiting Substance induces NFkB signaling in breast and prostate cancer cells. Mol Cell Endocrinol (2003) 0.96
Müllerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents. Proc Natl Acad Sci U S A (2001) 0.93
AMH induces mesonephric cell migration in XX gonads. Mol Cell Endocrinol (2003) 0.93
Müllerian-inhibiting substance type II receptor expression and function in purified rat Leydig cells. Endocrinology (1999) 0.89
Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the rat. Endocrinology (1992) 0.89
Periductal and matrix glycosaminoglycans in rat Mullerian duct development and regression. Dev Biol (1982) 0.88
The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells. J Clin Endocrinol Metab (1992) 0.88
Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian duct. Dev Biol (2008) 0.87
Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo. Cancer Res (1991) 0.87
Müllerian inhibiting substance inhibits testosterone synthesis in adult rats. J Androl (2001) 0.86
The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia. Int J Oncol (2009) 0.81
Sequence, genomic organization, and chromosomal location of the mouse Müllerian-inhibiting substance type II receptor gene. Biochem Biophys Res Commun (1997) 0.80
DiI analysis of cell migration during müllerian duct regression. Dev Biol (1995) 0.79
Detection of large-scale variation in the human genome. Nat Genet (2004) 49.18
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A (2006) 4.66
Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87
A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. Proc Natl Acad Sci U S A (2008) 3.57
Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. Nat Biotechnol (2011) 3.25
Sex determination and differentiation. N Engl J Med (2004) 3.07
Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril (2002) 2.10
Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. Dev Biol (2005) 2.07
Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat Genet (2007) 1.85
HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci U S A (2009) 1.45
Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proc Natl Acad Sci U S A (2008) 1.41
Dissecting spatio-temporal protein networks driving human heart development and related disorders. Mol Syst Biol (2010) 1.35
The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab (2002) 1.33
Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression. Development (2006) 1.26
The immunophilin FKBP12: a molecular guardian of the TGF-beta family type I receptors. Front Biosci (2004) 1.25
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci U S A (2012) 1.21
Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci U S A (2010) 1.20
Adult mouse myometrial label-retaining cells divide in response to gonadotropin stimulation. Stem Cells (2007) 1.18
Management and long-term follow-up of patients with types III and IV laryngotracheoesophageal clefts. J Pediatr Surg (2005) 1.17
Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res (2002) 1.15
Mullerian inhibiting substance acts as a motor neuron survival factor in vitro. Proc Natl Acad Sci U S A (2005) 1.14
MIS/AMH in the assessment of cryptorchidism and intersex conditions. Mol Cell Endocrinol (2003) 1.11
Chick pulmonary Wnt5a directs airway and vascular tubulogenesis. Development (2008) 1.10
Genetic and environmental risk factors in congenital heart disease functionally converge in protein networks driving heart development. Proc Natl Acad Sci U S A (2012) 1.08
Persistent Mullerian duct syndrome caused by both a 27-bp deletion and a novel splice mutation in the MIS type II receptor gene. Birth Defects Res A Clin Mol Teratol (2003) 1.07
Infants with Bochdalek diaphragmatic hernia: sibling precurrence and monozygotic twin discordance in a hospital-based malformation surveillance program. Am J Med Genet A (2005) 1.06
SATB1 expression is associated with biologic behavior in colorectal carcinoma in vitro and in vivo. PLoS One (2013) 1.04
Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res (2006) 1.02
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A (2006) 1.02
Intersex genetic anomalies with malignant potential. Curr Opin Pediatr (2006) 1.01
Congenital diaphragmatic hernia candidate genes derived from embryonic transcriptomes. Proc Natl Acad Sci U S A (2012) 1.01
New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 1.00
Late complications of newborn circumcision: a common and avoidable problem. Pediatr Surg Int (2010) 0.99
Congenital diaphragmatic hernia (CDH) etiology as revealed by pathway genetics. Am J Med Genet C Semin Med Genet (2007) 0.99
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance. Proc Natl Acad Sci U S A (2004) 0.99
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo. Proc Natl Acad Sci U S A (2002) 0.99
Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci U S A (2003) 0.98
Feedback inhibition of steroidogenic acute regulatory protein expression in vitro and in vivo by androgens. Endocrinology (2003) 0.98
Donnai-Barrow syndrome (DBS/FOAR) in a child with a homozygous LRP2 mutation due to complete chromosome 2 paternal isodisomy. Am J Med Genet A (2008) 0.96
MEK-1/2 inhibition reduces branching morphogenesis and causes mesenchymal cell apoptosis in fetal rat lungs. Am J Physiol Lung Cell Mol Physiol (2002) 0.96
Endothelial cells promote migration and proliferation of enteric neural crest cells via beta1 integrin signaling. Dev Biol (2009) 0.95
Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase. FASEB J (2010) 0.95
Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers. Future Oncol (2010) 0.95
Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril (2005) 0.93
Uterine leiomyomas exhibit fewer stem/progenitor cell characteristics when compared with corresponding normal myometrium. Reprod Sci (2009) 0.92
c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction. Endocrinology (2007) 0.92
Focal Mullerian duct retention in male mice with constitutively activated beta-catenin expression in the Mullerian duct mesenchyme. Proc Natl Acad Sci U S A (2010) 0.90
Characterization of the chromosome 1q41q42.12 region, and the candidate gene DISP1, in patients with CDH. Am J Med Genet A (2010) 0.90
Congenital diaphragmatic hernia interval on chromosome 8p23.1 characterized by genetics and protein interaction networks. Am J Med Genet A (2012) 0.89
Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells. J Biol Chem (2003) 0.88
Serum Müllerian Inhibiting Substance/anti-Müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology. Gynecol Oncol (2009) 0.88
Circumcised hypospadias. Pediatr Surg Int (2008) 0.88
Mullerian inhibiting substance: an update. Adv Exp Med Biol (2002) 0.88
Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian duct. Dev Biol (2008) 0.87
Congenital adrenal hyperplasia: surgical considerations required to repair a 46,XX patient raised as a boy. J Pediatr Surg (2003) 0.86
Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism. Cancer Res (2007) 0.85
Double-chimney technology for treating secondary type I endoleak after endovascular repair for complicated thoracic aortic dissection. J Vasc Surg (2011) 0.85
Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer. BMC Cancer (2014) 0.85
Measurement of Mullerian inhibiting substance facilitates management of boys with microphallus and cryptorchidism. J Clin Endocrinol Metab (2002) 0.85
Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-kappaB-dependent Smad-independent mechanism. Mol Endocrinol (2006) 0.83
Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications. Mol Cell Endocrinol (2003) 0.83
Expression analysis and evolutionary conservation of the mouse germ cell-specific D6Mm5e gene. Dev Dyn (2006) 0.82
Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis. J Clin Endocrinol Metab (2012) 0.82
Steroidogenic activities in MA-10 Leydig cells are differentially altered by cAMP and Müllerian inhibiting substance. J Steroid Biochem Mol Biol (2004) 0.81
The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia. Int J Oncol (2009) 0.81
Müllerian-inhibiting substance inhibits rat Leydig cell regeneration after ethylene dimethanesulphonate ablation. Biol Reprod (2003) 0.81
Distribution of ERK1/2 and ERK3 during normal rat fetal lung development. Anat Embryol (Berl) (2005) 0.81
Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance. Protein Expr Purif (2009) 0.79
Serum müllerian-inhibiting substance in Down's syndrome pregnancies. Hum Reprod (2007) 0.78
Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells. Int J Oncol (2011) 0.77
Müllerian inhibiting substance is anterogradely transported and does not attenuate avulsion-induced death of hypoglossal motor neurons. Exp Neurol (2010) 0.77